Objectives: Was to investigate the effect of treatment with an IM injection, a mega dose of vitamin D3 (10 000 IU/kg) on the clinical, biochemical and radiological parameters of 40 rachitic children with vitamin D deficiency (VDD) over a period of 3 months. Design: In this prospective study we evaluated the clinical, biochemical and radiological responses of an IM injection of cholecalciferol (10 000 IU/kg) for 3 months. Results: At presentation, the most frequent manifestations were enlarged wrist joints, hypotonia, irritability, cranial bossing, wide anterior fontanel, bow legs, delayed teething and walking and Harrison's sulcus with chest rosaries. Short stature (length SDS < À2) was recorded in 30% of patients. Craniotabes and hypocalcemic tetany were the least common presentations. In VDD children the most frequent biochemical abnormality was high alkaline phosphatase (ALP) (100%), followed by low phosphate (PO 4 ) (75%) and low calcium (Ca) (12.5%). One month after treatment, serum Ca, PO 4 and 25(OH)D concentrations were normal. Three months after the injection, serum level of ALP and parathormone (PTH) decreased to normal. The majority of patients (87.5%) had serum 25(OH)D level ! 20 ng/ml, but some (12.5%) had level <20 ng/ml. Hypercalcemia was not recorded in any patient during the 3-month-period. Significant cure of all symptoms and signs related to vitamin D deficiency had been achieved in all children. Leg bowing showed significant improvement in all patients but was still evident in one third. Complete healing of the radiological evidence of rickets was achieved in 95% of all children. Conclusion: An IM injection of a mega dose of cholecalciferol is a safe and effective therapy for treatment of VDD rickets in infants and toddlers with normalization of all the biochemical parameters and healing of radiological manifestations. Measurement of serum 25(OH)D level is highly recommended in all short children with a clear need for a general vitamin D supplementation for all infants and young children in Qatar.
Introduction
Without vitamin D, only 10-15% of dietary calcium and about 60% of phosphorus is absorbed. The active form, 1,25-dihydroxyvitamin D markedly increases the efficiency of intestinal calcium and phosphorus absorption [1] [2] [3] [4] [5] . Serum levels of 25-hydroxyvitamin D are directly related to bone mineral density with a maximum density achieved when the 25-hydroxyvitamin D level reached 40 ng/ml or more [6] . Serum levels below 30 ng/ml are associated with a significant decrease in intestinal calcium absorption [5] . In adolescents, children and adults; this is associated with increased parathyroid hormone [7] [8] [9] . Parathyroid hormone enhances the tubular reabsorption of calcium and stimulates the kidneys to produce 1,25-dihydroxyvitamin D [1] [2] [3] [4] . Parathyroid hormone also activates osteoblasts, which stimulate the transformation of preosteoclasts into mature osteoclasts [1] [2] [3] . Osteoclasts dissolve the mineralized collagen matrix in bone, causing osteopenia and osteoporosis and increasing the risk of fracture [10] [11] [12] [13] . However, the available evidence is not sufficient to support the use of bone mineral content or parathyroid hormone concentrations in infants and young children as functional outcomes to define deficient or sufficient levels of 25(OH)D.
Children with vitamin D deficiency should be aggressively treated to prevent rickets [1, [14] [15] [16] . A cost-effective method of correcting vitamin D deficiency (VDD) and maintaining adequate levels is to give patients a large single dose of vitamin D, followed by a maintenance dose [2, [14] [15] [16] . In adults strategies such as having patients take 100 000 IU of vitamin D 3 once every 3 months have been shown to be effective in maintaining 25-hydroxyvitamin D levels at 20 ng/ml or higher and are also effective in reducing the risk of fracture [17] .
Higher doses of 100 000-300 000 IU have been administered orally or intramuscularly 6-monthly or once-yearly quite safely without causing hypercalcemia or renal impairment. [18] [19] [20] . A Turkish study by Cesur et al. [22] , compared the effects of oral administration of 150 000, 300 000 and 600 000 IU of vitamin D in 56 infants and toddlers with nutritional vitamin D rickets. The authors reported resolution of the disease process with all three doses, but six of the patients in the 600 000 IU-dose group (n ¼ 28) and two of the patients in the 300 000 IU-dose group (n ¼ 28) developed hypercalcemia, although none of these patients had symptoms of hypercalcemia. Therefore, the authors suggested that administering 150 000 IU of vitamin D might be sufficient to treat rickets [21] .
The effect of treatment using a single intramuscular mega-doses of vitamin D 3 on the clinical, biochemical and radiological manifestations of infantile rickets has not been well-studied. Intramuscular mega-dose of vitamin D was used in two studies both in children and adults (300 000 U and 600 000 U, respectively) with vitamin D deficiency and reported improvement of biochemical and radiological abnormalities [19, 20] .
The objective of this study was to evaluate the clinical, biochemical and radiological response to a single intramuscular large dose of vitamin D 3 (10 000 IU/kg) in infants and toddlers presented with VDD rickets.
Patients and Methods
In this prospective study 40 infants and toddlers up to and including 3 years of age with nutritional rickets attending the Pediatric outpatient Clinic at Hamad Medical Centre, Doha, Qatar, between January 2007 and December 2007 were studied. Qatar has a sunny hot weather allover the year with no seasonal variation in the incidence of rickets. Mothers breast feeding their infants are advised to give oral vitamin D in the form of drops (400 IU/day) starting on the fourth month of life. However, rickets is still a common disease in Qatar because of lack of exposure to the sun (avoiding the hot humid weather by being indoors, with the majority of mothers completely covered and veiled when outdoors 
Ethical approval
Research Ethics Board, Hamad Medical Centre, Doha Qatar approved the protocol of the study and informed consents were obtained from all the parents of the children included in this study. All patients were subjected to the following:
(1) Detailed history taking including nutritional intake and exposure to sun. (2) Physical examination including clinical manifestations of rickets. (3) Anthropometric measurements included weight, length, and head circumference. (4) Length standard deviation scores (LSDS), length growth velocity standard deviation scores (GVSDS) and body mass index were calculated prospectively before and at least 6 months or more after treatment. Annualized length velocity (GV) was calculated from length measurements taken 6 months apart. Length was measured with a infant/child height/length measuring board: this board has 130 cm capacity (collapses to 75 cm) and has 0.1 cm increments, with the sliding headfoot piece. (Shorr Productions; 17802 Shotley Bridge Place; Olney, MD 20832, USA). The standard deviation of the difference between blind triplicate length measurements of 20 children was 0.12 cm. Weight (child lightly clothed) was measured using an electronic scale with Digital Display. Standard deviation scores (SDS) were calculated for length and length velocity (using Tanner, Whitehouse, and Takaishi standards [11, 12] and body mass index (BMI) (using Cole, Freeman, and Preece standards) [13] . (5) 
During clinic visits the anthropometric parameters were assessed and recorded and the laboratory tests repeated. Serum Ca, PO 4 , ALP concentrations were measured every 4 weeks. Serum PTH and 25(OH)D concentrations were measured after 3 and 6 months.
Children with plasma 25(OH)D levels less than 10 ng/ml were considered to have VDD. The presence or absence of radiological evidence of rickets was determined from routine radiological reports.
The radiographs were read by a single radiologist (EMB) who was blind for the biochemical data of the patients.
PTH and 25(OH)D were measured by radioimmunometric assay using reagents purchased from Mediagnost; Reutlingen, Germany [21] . Intraassay coefficient of variations (CVs) were 6.9% and 5.8%, respectively, and interassay CVs were 8.9% and 8.2%, respectively. Results are expressed as the mean AE SD and analyzed by paired student t-test to compare growth parameters and analyte concentrations before vs. after treatment. Correlation and linear regression analysis were used to investigate the relation between variables.
Infants with VDD rickets were treated with a mega-dose of vitamin D3 (10 000 U/kg, maximum 150 000 U) intramuscularly in the gluteal region [22] . The intramuscular route was selected to avoid the poor compliance to oral medication experienced in our clinics. Parents preferred this mode of therapy for their children vs. daily oral doses of vitamin D. None of the patients received oral vitamin D supplements after the injection. They were not maintained on oral vitamin D after the initial injection for the duration of the study. The diet in Qatar is deficient in vitamin D with no vitamin D added to food products that a toddler might eat apart from the fortified milk formula.
Results
A total of 40 children were identified with vitamin D deficiency rickets during the study period between the age of 7 and 23 months (mean age 16.1 AE 4.5 months). The majority of infants were exclusively breast-fed (35/40) for more than 6 months. Ninety percent (36/40) of them were still on breast feeding at presentation but only 60% (24/40) were still on breast feeding after 6 months of follow-up. Major clinical manifestations (Table 1) included: enlarged wrist joints, hypotonia, irritability, skull bossing, wide anterior fontanel, bow legs, delayed teething and walking and Harrison's sulcus with chest rosaries. Short stature (length SDS <À2) was recorded in 30% of patients. Craniotabes and hypocalcemic tetany were the least common presentations. Improvement of all these manifestations occurred after treatment. However, leg bowing was still evident in one-third of patients who presented with bow legs.
At presentation hypophosphatemia was present in 75% of whereas hypocalcemia was present in 12.5% of patients. One month after treatment serum PO 4 and Ca concentrations were normal in all patients. After 3 and 6 months of treatment, anthropometrics (Table 2 ) showed significant improvement. Both the LSDS and annualized GVSDS increased significantly (3-month-data shown). Circulating concentrations of ALP and PTH decreased significantly to normal values. The circulating 25(OH)D concentrations were >20 ng/ml in the majority of children (87.5%) but was <20 ng/ml in 12.5% of them. Only one child had 25(OH)D level <10 ng/ml. None of the children had hypercalcemia or elevated serum creatinine at any measurement after the injection.
The changes in serum concentrations of 25(OH)D correlated significantly with the changes of serum calcium and negatively with changes of ALP. Changes in the circulating PTH concentrations correlated significantly with changes of ALP and negatively with changes in PO 4 levels ( Table 3) .
Radiological manifestations including the epiphysis were present in all cases but diaphyseal changes were present in 82.5% at presentation. VDD patients with normal serum calcium and phosphate concentrations had mild broadening of the joint space, mild or no epiphyseal changes and normal metaphyseal calcification and diaphyseal thickness (Fig. 2) . VDD patients with low serum phosphate but normal serum calcium concentrations had irregular/faint (fraying) line of ossification at metaphyseal front with excessive osteoid (cupping) and some metaphyseal and diaphyseal demineralization. VDD patients with low phosphate and calcium concentrations (dysadapted) had absent line of ossification at metphyseal front, excessive osteoid deposition (very wide wrist space) with cupping, marked decalcification of the metaphysis and diaphysis of long bones (very thin cortex) with subperiosteal erosion of the shafts (Fig. 4) . Three months after the injection both the epiphyseal and diaphyseal changes were normalized in the majority of cases (95%). Six months after the injection, 25(OH)D decreased significantly in 39 of the 40 children to a level below 20 ng/ml. Four out of the 40 had serum 25(OH)D level <10 ng/ml (Fig. 1) . [22] [23] [24] [25] [26] [27] [28] .
Discussion
We have presented 40 cases of vitamin D deficiency in children managed by hospital pediatric department over a 1-year period. Vitamin D deficiency remains the commonest cause of newly presenting hypocalcaemia in our pediatric department after the neonatal period. However, hypocalcemia was less prevalent (12.5%) in our rachitic children compared to hypophosphatemia (75%). This is expected because of the protective effect of secondary hyperparathyroidism on maintaining serum calcium concentration in the normal range. In a VDD state, only 10-15% of dietary calcium and 50-60% of dietary phosphorus are absorbed. The poor absorption of calcium causes a decrease in serum-ionized calcium levels. This is immediately recognized by the calcium sensor in the parathyroid glands, resulting in an increase in the secretion of parathyroid hormone (PTH). PTH conserves calcium by increasing tubular reabsorption of calcium in both the proximal and distal convoluted tubules. However, PTH enhances the expression of Receptor Activator for Nuclear Factor B Ligand (RANKL) on osteoblasts to increase the production of mature osteoclasts to mobilize calcium stores from the skeleton. PTH also decreases phosphorus reabsorption in the kidney, causing loss of phosphorus into the urine and hypophosphatemia [1, [29] [30] [31] [32] . Although serum calcium level is usually normal in the majority of VDD with rickets, it is the low serum phosphorus that leads to an inadequate calciumphosphorus product, which is necessary to mineralize the osteoid laid down by osteoblasts [1, [29] [30] [31] [32] . This explains the florid appearance of radiological rachitic manifestations in our VDD patients with hypophosphatemia vs. those with normophosphatemia. The secondary hyperparathyroidism stimulates the kidneys to produce 1,25(OH)2D. Only when the calcium stores in the skeleton are totally depleted will the infant or child become hypocalcemic. This is evident in our patients with hypocalcemia, who had more severe osteoporotic changes in the diaphysis compared with normocalcemic patients.
Thirty percent of our rachitic children were significantly short (LSDS <À2) at presentation, with slow growth velocity. Many factors can contribute to impaired linear growth in these children including: (i) defective mineralization and increased size of the hypertrophic layer of the growth plate with the deposition of excessive osteoid (100% of patients), (ii) deformities of the long bones of the lower limbs with bowing of both femur and tibia due to weakening of the shafts (70% of our patients), (iii) hypotonia (of the back muscles and ligaments with tendency to postural kyphosis or kyphoscoliosis) (62.5% of our patients) (iv) possible effect of vitamin D deficiency on growth hormone (GH)/insulin like growth factor I (IGF-I) axis [28] and (v) repeated infections (45% of our patients) that might be due to the lack of vitamin D effect on immune system with subsequent effect on the nutritional status of the infant. Marked improvement of linear growth after therapy implements the necessity to investigate vitamin D status in every short child in countries where vitamin D deficiency is still prevalent. Some data suggest that in infants and children VDD may induce an adaptive state associated with slow growth and decreased metabolic demands for Ca before the appearance of clinical rickets [3, 11, 13] .
Following intramuscular cholecalciferol injection, serum 25(OH)D levels increased in all participants and after 3 months of the injection it was t was >20 ng/ml in 87.5% of patients. Serum Ca and PO 4 concentrations were normal 1 month after the injection. Three months after the injection, all biochemical and radiological manifestations were normalized. Clinical improvement was complete in all the patients with a residual degree of bow-legs in a minority. None of the patients had hypercalcemia or increased serum creatinine at any time after injecting vitamin D. However, the significant decrease of circulating 25(OH)D level 6 months after the injection proved that this dose may not be enough to maintain normal level of 25(OH)D in these children for 6 months.
Conclusion
An IM injection of a mega dose of cholecalciferol is a safe and effective therapy for treatment of rachitic infants and toddlers with VDD for 3 months had normalization of all the biochemical parameters and healing of radiological manifestations. vitamin D supplementation for all infants and children in Qatar. In addition supplementing children food with vitamin D appears to be useful means of prevention of rickets in Qatar.
